[클리니컬 히스토리] 강스템 오스카, 임상 2a 검증…DMOAD 주목

Oscar aims to be a breakthrough DMOAD, addressing the high unmet need for structural cartilage repair rather than just temporary pain relief. The successful completion of Phase 2a observation is a critical milestone that will determine its global Licensing-out valuation and validate the commercial potential of stem cell-based regenerative medicine.